|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | P.O. Box 3454 |
Address2 |
|
City | Oakton |
State | VA |
Zip Code | 22124 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401027897-51
|
||||||||
|
6. House ID# 422190005
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: James Edwards |
Date | 7/6/2020 9:06:28 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 2082/H.R. 3666 (STRONGER Patents Act)
Trade-related intellectual property policy/practices/encroachment by foreign countries/companies against U.S. competitiveness interests - China, Committee on Foreign Investment in the United States review of Chinese acquisitions and joint ventures, United States-Mexico-Canada Agreement IP chapter, International Trade Commission exclusion of U.S. patent-infringing imports, ITC baseband chip set patent infringement remedy, intellectual property exclusivity and protections in trade agreements
Piracy of online and streaming copyrighted content
Compulsory licensing - S. 377/H.R. 1046 (Medicare Negotiation and Competitive Licensing Act), S. 102/H.R. 465 (Prescription Drug Price Relief Act), S. 977 (Transparent Drug Pricing Act)
NIST Return on Investment Initiative for Unleashing American Innovation
S. 344/H.R. 990 (Hatch-Waxman Integrity Act)
FTC/patent licensing as exclusive property right
Bayh-Dole Act/technology transfer, march-in rights
Procedural and evidentiary standards used at Patent Trial and Appeal Board
PTO patentable subject matter eligibility guidance
Section 101 patentable subject matter reform
Injunctive relief from willful infringement
DOJ-DOC withdrawal of 2013 Policy Statement on Remedies for Standards-Essential Patents Subject to Voluntary F/RAND Commitments
S. 1273/H.R. 2426 (Copyright Alternative in Small-Claims Enforcement (CASE) Act)
S. 1416 (Affordable Prescriptions for Patients Act)
Obviousness/No Combination Drug Patents Act
H.R. 4398/H.R. 5133 (Affordable Prescriptions for Patients Through Promoting Competition Act)
H.R. 3991 (Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act)
H.R. 5478 (Inventor Rights Act)
Patent licensing/standards-essential patents/U.S. technological leadership in 5G and other technologies/economic and national security implications
DOJ-PTO-NIST 2019 revised Joint Statement on Remedies for Standards-Essential Patents Subject to Voluntary F/RAND Commitments
Efficient infringement
Digital Millennium Copyright Act modernization
Patent Trial & Appeal Board Covered Business Methods program
PTAB Rules of Practice for Instituting on All Challenged Patent Claims and All Grounds and Eliminating the Presumption at Institution Favoring Petitioner as to Testimonial Evidence (Docket No. PTO-P-2019-0024)
S. 3630 (Facilitating Innovation to Fight Coronavirus Act)
Denial of rights of exclusivity for COVID-19-related innovations
H.R. 7366 (Restoring Americas Leadership in Innovation Act)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Patent & Trademark Office (PTO), Justice - Dept of (DOJ)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Edwards |
|
LD, Rep. Ed Bryant; LA/Press Secretary, Rep. John Duncan; Special Assistant, Senate Judiciary Committee |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code RES
16. Specific lobbying issues
Waters of the United States rule repeal - by regulatory reform of WOTUS, in appropriations
S.Res. 59/H.Res. 109 (Green New Deal resolution calling for the socialistic federal takeover of private property of American citizens and organizations and extinction of any meaningful private property rights in the United States)
Land management/acquisition
Public access to federally owned lands for sports, recreation, mining, commercial use
Social Costs of Carbon project termination
EPA regulatory and permitting reform
Draft Environmental Impact Statement for the Pebble Mine Project
H.R. 1373 (Grand Canyon Centennial Protection Act)
H.R. 2181 (Chaco Cultural Heritage Area Protection Act)
H.R. 3405 (Uranium Classification Act)
Methane Rule reform
Regulatory fairness and due process/National Environmental Policy Act reform (Docket No. CEQ-2019-0003-0001)
Navigable Waters Protection Rule definition of waters of the United States (Docket No. EPA-HQ-OW-2018-0149, FRL-10004-88-OW)
H.R. 7061 (American Critical Mineral Exploration and Innovation Act)
S. 3422 (Great American Outdoors Act)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Edwards |
|
LD, Rep. Ed Bryant; LA/Press Secretary, Rep. John Duncan; Special Assistant, Senate Judiciary Committee |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
S. 215/H.R. 218 (Death Tax Repeal Act)
H.R. 3301 (Taxpayer Certainty and Disaster Tax Relief Act)
Wealth tax
Treasury Dept. Estate and Gift Taxes Regulation re Difference in the Basic Exclusion Amount
H.R. 5377 (Restoring Tax Fairness for States and Localities Act) SALT deductibility cap repeal
H.R. 6690 (BEAT CHINA Act) tax incentives to relocate factories to U.S.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Edwards |
|
LD, Rep. Ed Bryant; LA/Press Secretary, Rep. John Duncan; Special Assistant, Senate Judiciary Committee |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Proposed International Pricing Index (IPI) payment model for drugs administered under Medicare Part B
S. 377/H.R. 1046 (Medicare Negotiation and Competitive Licensing Act)
Reform of drug manufacturer rebates to third parties (e.g., pharmaceutical benefits managers, insurers)
Proposed binding arbitration for enacting government price controls under Medicare Part D
Inflationary penalty as government price controls in Medicare Part D/S. 2543 (Prescription Drug Pricing Reduction Act)
S. 1129/H.R. 1384 (Medicare for All Act)
Single-payer health care
Government price controls on health care products, services, providers, payers
H.R. 3 (Elijah E. Cummings Lower Drug Costs Now Act) drug price controls through international reference pricing, direct federal price dictation, confiscatory penalty on the most innovative medicines
Importation of Prescription Drugs Proposed Rule (Docket No. FDA-2019-N-5711)
H.R. 1425 (Patient Protection and Affordable Care Enhancement Act)
H.R. 6674 (Medicare Crisis Program Act)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Edwards |
|
LD, Rep. Ed Bryant; LA/Press Secretary, Rep. John Duncan; Special Assistant, Senate Judiciary Committee |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |